Antipsychotic Drugs Market Size, Explosive Growth Opportunity, Regional Analysis Forecast till 2027
Global " Antipsychotic Drugs Market" 2020 report includes the market strategy, market orientation, expertise opinion and knowledgeable information. Report provides market growth and Revenue, market share and size that helps to understand future prospects. The Antipsychotic Drugs report also covers the current market information, porter's five forces analysis with threat of new entrants, threat of substitute products and services, key challenges, opportunities in Antipsychotic Drugs Industry.
Request a Sample Copy of the Research Report:
https://www.fortunebusinessinsights.com/enquiry/sample/antipsychotic-drugs-market-101390
The schizophrenia segment emerged dominant in the global ’antipsychotic
drugs market share‘ in 2018. The segment had acquired an astonishing 45.2% of
the global antipsychotic drugs market share in the same year owing to the
rising prevalence of the disorder. This information is published in a report by
Fortune Business Insights, titled, “Antipsychotic Drugs: Global Market
Analysis, Insights and Forecast, 2019-2026.” According to the report, the
global market was worth US$ 14,963.5 Mn in 2018. However, Fortune Business
Insights predicts that the global market will reach US$ 20,539.5 Mn by 2026,
exhibiting a CAGR of 4.0% in the forecast period.
The report on antipsychotic drugs
market provides insights into growth opportunities for investors and businesses
alike and growth drivers and trends in the market. It offers quantitative and
qualitative information on the drivers and growth rate of the segments in the
market. The report also comprises of extensive primary and secondary research
which aid in providing clients with a clear picture of the anticipated market size
and current market scenario.
Rapid Shift Towards Advanced and Safe Drugs to Favor Growth in North
America
Geographically, the global
antipsychotic drugs market is grouped into Latin America, Asia Pacific, North
America, the Middle East and Africa, and Europe. Amongst these regions, North
America had acquired US$ 9,307.3 Mn antipsychotic drugs market revenue in the
year 2018. The growth is attributed to the increasing patient pool suffering
from psychotic disorders in the region. Additionally, a rapid shift of these
patients towards safe antipsychotic drugs for the treatment of schizophrenia,
bipolar disorder, and other
psychotic diseases is expected to drive the antipsychotic drugs market in this
region. Several healthcare organizations in North America have also begun
promoting such drugs for treatment.
In
Asia Pacific, emerging countries, such as India, China, and other Southeast
Asian countries have a large patient pool who are suffering from various
disorders, especially schizophrenia. Moreover, the populace residing in these
countries are preferring second-generation drugs over first-generation
antipsychotic drugs. It is because of the increasing healthcare expenditure and
increasing awareness programs regarding the usage of these drugs. Fortune Business
Insights predicts that Europe would follow the footsteps of North America and
would remain in the second position throughout the forecast period. The growth
is attributed to a rise in the patient population and increasing incidence of
psychotic diseases.
Table Of Content :
1.
Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2.
Executive Summary
3.
Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4.
Key Insights
4.1. Overview of Prevalence of Psychiatric
Disorders by Key Regions
4.2. Pipeline Analysis
4.3. Key Industry Developments
4.4. New Product Launches
4.5. Analysis of the Cost and Burden of Mental
Health Disorders
4.6. Analysis of Antipsychotics in Treatment of
Dementia
4.7. Analysis of First Generation Antipsychotics
versus Second & Third Generation Antipsychotics
4.8. Overview of R&D Initiatives
Continue…
An Overview of the Impact of COVID-19 on this Market :
The
emergence of COVID-19 has brought the world to a standstill. We understand that
this health crisis has brought an unprecedented impact on businesses across
industries. However, this too shall pass. Rising support from governments and
several companies can help in the fight against this highly contagious disease.
There are some industries that are struggling and some are thriving. Overall,
almost every sector is anticipated to be impacted by the pandemic.
We
are taking continuous efforts to help your business sustain and grow during
COVID-19 pandemics. Based on our experience and expertise, we will offer you an
impact analysis of corona virus outbreak across industries to help you prepare
for the future.
For more information visit :
https://www.fortunebusinessinsights.com/industry-reports/antipsychotic-drugs-market-101390
Indivior, Otsuka, Allergan and Other Market Players Receive Fast Track
Approvals
Fortune Business Insights has
listed a few key developments that have occurred in the global antipsychotic drugs
market since the past few years:
·
Indivior PLC, a specialty
pharmaceuticals business based in the U.K., declared in July 2018 that it
received FDA approval for Perseris, a long-acting injectable (LAI) containing
risperidone. It is used to treat schizophrenia in adults. Perseris uses the
extended-release delivery system that provides a certain level of risperidone
which sustains over a month. According to the company, the FDA approval will
support adult patients and their healthcare providers by providing a
technologically advanced treatment option.
·
Otsuka Pharmaceutical Co., Ltd., a
pharmaceutical company, headquartered in Tokyo, announced the launch of Rexulti
in Japan in April 2018. Rexulti is available in both 1mg and 2mg variants for
the treatment of schizophrenia. It is already available in the pharmacies in
Australia, Canada, and the U.S. The efficacy and safety of Rexulti were
examined in four clinical phase III studies that were controlled by placebo.
The tablets were superior for the treatment of schizophrenia when provided at
specific dosages. Otsuka recommends giving the patients a lower dose during the
initial treatment procedure and then slowly increase the dosage over time. They
are to be consumed regularly with or without meals.
·
Allergan, a pharmaceutical company
based in Ireland, declared that the FDA approved Vraylar in May 2019. As per
the approval, Vraylar can now be used in the treatment of depressive episodes
that are associated with bipolar depression (bipolar I disorder) in adult patients.
In the U.S., Vraylar can also be used to treat manic episodes occurring due to
bipolar I disorder.
Fortune Business Insights has profiled some of the prominent market
players operating in the global antipsychotic drugs market. They are as follows:
•
H. Lundbeck A/S
•
Otsuka Pharmaceutical Co., Ltd.
•
Janssen Pharmaceuticals, Inc.
•
Eli Lilly and Company
•
AstraZeneca
•
ALLERGAN
•
Vanda Pharmaceuticals Inc.
•
Sumitomo Dainippon Pharma Co., Ltd.
•
Alkermes plc
•
Pfizer Inc.
•
Bristol-Myers Squibb Company
•
Other Prominent Players
Have Any Query? Ask Our Experts:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antipsychotic-drugs-market-101390
Global Antipsychotic
Drugs Market Segmentation :
By Disease
• Schizophrenia
• Bipolar
Disorder
• Unipolar
Depression
• Dementia
• Others
By Therapeutic Class
• First
Generation
• Second
Generation
• Third
Generation
By Distribution Channel
• Hospital
Pharmacies
• Retail
Pharmacies
• Online
Pharmacies
• Others
By Geography
• North
America (the USA and Canada)
• Europe
(UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Asia
Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia
Pacific)
• Latin
America (Brazil, Mexico and Rest of Latin America)
• Middle
East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Secondary Data
Sources That We Refer To:
•
Annual reports, investor
presentation, SEC filings, and press releases of companies operating in the
market
•
Studies published by relevant
associations MedTech Europe; American College of Radiology; Cancer Council
Australia; Japan Hospital Association, etc.), government sources (Centers for
Disease Control & Prevention, Ministry of Health, Labour & Welfare,
Japan; National Health Service, England, etc.), international organizations
(World Health Organization, The Organization for Economic Co-operation and
Development, Eurostat, etc.), and articles published by Research Gate, NCBI,
etc.
•
Website, reports, and press
releases of end user facilities – Hospitals, Ambulatory Surgery Centres,
Clinics
•
Industry journals and paid
databases
Secondary Research Is Conducted To
Derive The Following Information:
•
Details such as revenues,
market share, strategies, growth rate, product & their pricing by
region/country for all major companies
•
Details in relation to
prevalence, incidence, patient numbers, distribution of patients, average price
of treatment, etc.
•
Number of end user facilities
by region/country and average annual spending or procurement of devices by type
of end user facility
•
Number of procedures and
average price of procedures
•
Replacement rate and pricing of
capital equipment
•
Market dynamics in relation to
the market under focus – Drivers, restraints, trends, and opportunities
•
Market & technological
trends, new product developments, product pipeline.
More Trending Topics from Fortune
Business Insights :
About Us:
Fortune Business Insights(TM) offers expert corporate analysis and accurate
data, helping organizations of all sizes make timely decisions. We tailor
innovative solutions for our clients, assisting them to address challenges
distinct to their businesses. Our goal is to empower our clients with holistic
market intelligence, giving a granular overview of the market they are
operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis
to help companies achieve sustainable growth. Our team of experienced analysts
and consultants use industry-leading research tools and techniques to compile
comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights(TM) we aim at highlighting the most lucrative
growth opportunities for our clients. We, therefore, offer recommendations,
making it easier for them to navigate through technological and market-related
changes. Our consulting services are designed to help organizations identify
hidden opportunities and understand prevailing competitive challenges
Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment